Dodge & Cox Incyte Corp Transaction History

Dodge & Cox

$164 Billion
Q1 2025

A detailed history of Dodge & Cox transactions in Incyte Corp stock. As of the latest transaction made, Dodge & Cox holds 14,864,328 shares of INCY stock, worth $1.02 Billion. This represents 0.55% of its overall portfolio holdings.

Number of Shares

14,864,328

Previous 14,919,633 0.37%

Holding current value

$1.02 Billion

Previous $1.03 Billion 12.66%

% of portfolio

0.55%

Previous 0.64%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$60.0 - $75.26 $3.32 Million - $4.16 Million	-55,305 Reduced 0.37%	14,864,328 $900 Million
Q4 2024 Feb 13, 2025	SELL	$65.08 - $83.38 $23.2 Million - $29.7 Million	-356,460 Reduced 2.33%	14,919,633 $1.03 Billion
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $186,322 - $222,982	-3,250 Reduced 0.02%	15,276,093 $1.01 Billion
Q2 2024 Aug 13, 2024	SELL	$51.18 - $63.75 $7 Million - $8.71 Million	-136,700 Reduced 0.89%	15,279,343 $926 Million
Q1 2024 May 14, 2024	SELL	$56.55 - $66.59 $38.1 Million - $44.9 Million	-674,378 Reduced 4.19%	15,416,043 $878 Million
Q4 2023 Feb 15, 2024	SELL	$52.16 - $64.19 $17 Million - $20.9 Million	-325,690 Reduced 1.98%	16,090,421 $1.01 Billion
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $165 Million - $189 Million	-2,861,849 Reduced 14.85%	16,416,111 $948 Million
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $3.31 Million - $4.1 Million	-54,350 Reduced 0.28%	19,277,960 $1.2 Billion
Q1 2023 May 12, 2023	SELL	$70.23 - $86.01 $2.15 Million - $2.63 Million	-30,625 Reduced 0.16%	19,332,310 $1.4 Billion
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $28.9 Million - $36.2 Million	-430,465 Reduced 2.17%	19,362,935 $1.56 Billion
Q3 2022 Nov 10, 2022	SELL	$66.18 - $82.86 $18.2 Million - $22.7 Million	-274,445 Reduced 1.37%	19,793,400 $1.32 Billion
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $133 Million - $167 Million	2,007,555 Added 11.12%	20,067,845 $1.52 Billion
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $92.6 Million - $112 Million	1,402,704 Added 8.42%	18,060,290 $1.43 Billion
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $11.5 Million - $13.4 Million	181,150 Added 1.1%	16,657,586 $1.22 Billion
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $198 Million - $242 Million	2,878,900 Added 21.17%	16,476,436 $1.13 Billion
Q2 2021 Aug 13, 2021	BUY	$79.87 - $87.53 $741 Million - $812 Million	9,280,144 Added 214.95%	13,597,536 $1.14 Billion
Q1 2021 May 14, 2021	BUY	$76.02 - $100.5 $81 Million - $107 Million	1,064,862 Added 32.74%	4,317,392 $351 Million
Q4 2020 Feb 11, 2021	SELL	$80.74 - $97.7 $2.94 Million - $3.56 Million	-36,401 Reduced 1.11%	3,252,530 $283 Million
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $32.7 Million - $42.2 Million	-384,819 Reduced 10.47%	3,288,931 $295 Million
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $23.7 Million - $34.7 Million	-318,850 Reduced 7.99%	3,673,750 $382 Million
Q1 2020 May 14, 2020	BUY	$63.18 - $85.97 $14.8 Million - $20.1 Million	233,850 Added 6.22%	3,992,600 $292 Million
Q4 2019 Feb 13, 2020	SELL	$73.04 - $95.72 $11.2 Million - $14.7 Million	-153,525 Reduced 3.92%	3,758,750 $328 Million
Q3 2019 Nov 13, 2019	SELL	$72.82 - $86.52 $21.6 Million - $25.7 Million	-296,900 Reduced 7.05%	3,912,275 $290 Million
Q2 2019 Aug 13, 2019	SELL	$73.52 - $88.7 $3.39 Million - $4.1 Million	-46,175 Reduced 1.09%	4,209,175 $358 Million
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $969,290 - $1.34 Million	15,250 Added 0.36%	4,255,350 $366 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $248 Million - $297 Million	4,240,100 New	4,240,100 $270 Million

Others Institutions Holding INCY

# of Institutions

700

Shares Held

195M

Call Options Held

564K

Put Options Held

331K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dodge & Cox, based on Form 13F filings with the SEC.

News

Stay updated on Dodge & Cox with notifications on news.

Account